An expert-led webinar designed to address the critical need for education about the potential future of neoadjuvant therapy for early-stage NSCLC

IDENTIFY patients with newly diagnosed MM for whom treatment with an anti-CD38 monoclonal antibody-based therapeutic regimen would be appropriate

Explore the clinical evidence surrounding the role of HER3 in various tumor types.

Outline how new or emerging options may fit into existing treatment algorithms for patients with uveal melanoma.

This activity provides an overview of molecular and clinical subtypes of lymphoma and the mechanisms by which targeted therapies work for molecular subtypes.

Review patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies

Assess the severity of hemophilia A according to clinical presentation and results of factor assays

Review diagnostic challenges that are specific to acquired, immune-mediated TTP (thrombotic thrombocytopenic purpura )